Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Arecor Therapeutics PLC

Healthcare GB AREC

69.0GBX
3.00(4.55%)

Last update at 2026-06-05T15:24:00Z

Day Range

68.0070.00
LowHigh

52 Week Range

35.40100.00
LowHigh

Fundamentals

  • Previous Close 66.00
  • Market Cap24.92M
  • Volume13396
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.34700M
  • Revenue TTM5.06M
  • Revenue Per Share TTM0.14
  • Gross Profit TTM 1.60M
  • Diluted EPS TTM-0.23

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -10.61800M -8.90100M -10.54200M -6.94500M -3.51234M
Minority interest - - - - -
Net income -10.23600M -8.55400M -9.26000M -6.16900M -2.75237M
Selling general administrative 6.18M 8.91M 5.55M 2.39M 1.64M
Selling and marketing expenses - 0.63M - - -
Gross profit 1.54M 4.57M 2.40M 1.16M 1.70M
Reconciled depreciation 0.45M 0.50M 0.34M 0.17M 0.17M
Ebit -10.59600M -8.88600M -10.63000M -5.97700M -3.42802M
Ebitda -10.15000M -8.39000M -10.17500M -6.29000M -3.26168M
Depreciation and amortization 0.45M 0.50M 0.46M -0.31300M 0.17M
Non operating income net other - - - - -
Operating income -10.69700M -9.17500M -10.63000M -5.97700M -3.42802M
Other operating expenses 15.75M 13.75M 13.03M 7.13M 5.13M
Interest expense 0.02M 0.01M 0.03M 0.02M 0.08M
Tax provision -0.38200M -0.34700M -1.28200M -0.77600M -0.75997M
Interest income 0.10M 0.28M 0.11M 0.00100M 0.00298M
Net interest income 0.08M 0.27M 0.08M -0.50600M -0.08428M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.38200M -0.34700M -1.28200M -0.77600M -0.75997M
Total revenue 5.05M 4.57M 2.40M 1.16M 1.70M
Total operating expenses 12.24M 13.75M 13.03M 7.13M 5.13M
Cost of revenue 3.51M 3.32M - - -
Total other income expense net 0.08M 0.27M 0.09M -0.96800M -0.08431M
Discontinued operations - - - - -
Net income from continuing ops -10.23600M -8.55400M -9.26000M -6.16900M -2.75237M
Net income applicable to common shares - - -9.26000M -6.16900M -2.75237M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 8.72M 15.38M 21.77M 20.92M 4.28M
Intangible assets 0.03M 1.81M 1.92M 0.03M 0.04M
Earning assets - - - - -
Other current assets 1.62M 0.78M 0.05M 2.20M 0.92M
Total liab 3.37M 5.85M 4.31M 2.37M 3.51M
Total stockholder equity 5.35M 9.53M 17.45M 18.55M 0.77M
Deferred long term liab - - - - -
Other current liab 2.08M 2.57M - 1.62M 0.84M
Common stock 0.38M 0.31M 0.31M 0.28M 0.03M
Capital stock 0.38M 0.31M 0.31M 0.28M 0.03M
Retained earnings -44.95800M -34.72200M -26.18100M -17.05100M -11.89189M
Other liab - - 0.50M - 0.21M
Good will 0.00000M 1.48M 1.48M - -
Other assets - - 0.05M 0.05M 0.05M
Cash 3.24M 5.09M 4.76M 18.32M 2.90M
Cash and equivalents - - - - -
Total current liabilities 3.26M 5.15M 3.73M 2.27M 1.41M
Current deferred revenue - 0.23M - - -
Net debt -3.00700M -4.75500M -4.47700M -18.08500M -0.90311M
Short term debt 0.24M 0.24M 0.20M 0.13M 0.11M
Short long term debt - - - - 0.00000M
Short long term debt total 0.23M 0.34M 0.29M 0.23M 2.00M
Other stockholder equity 34.68M 28.98M 43.33M 35.32M 12.64M
Property plant equipment - - 0.84M 0.33M 0.38M
Total current assets 8.23M 11.17M 17.48M 20.52M 3.82M
Long term investments - - - - -
Net tangible assets - - 14.05M 18.52M 0.74M
Short term investments 0.02M 1.66M 8.04M - -
Net receivables 2.87M 2.87M 3.49M 1.57M 0.86M
Long term debt - - - 0.00000M 1.70M
Inventory 0.48M 0.77M 1.13M - 0.00000M
Accounts payable 0.84M 2.25M 3.53M 0.52M 0.46M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 15.24M 14.97M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.06M 0.08M 0.05M 0.05M 0.05M
Deferred long term asset charges - - - - -
Non current assets total 0.49M 4.21M 4.29M 0.41M 0.46M
Capital lease obligations 0.23M 0.34M 0.29M 0.23M 0.30M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 1.72M 6.52M -7.99300M -0.06800M -0.04932M
Change to liabilities - - -2.19800M 0.84M 0.36M
Total cashflows from investing activities 1.72M 6.52M -7.99300M -0.06800M -0.04932M
Net borrowings 0.00900M 0.04M -0.46000M 2.39M 1.86M
Total cash from financing activities 5.65M -0.18000M 5.16M 20.93M 1.77M
Change to operating activities - - - - -
Net income -10.61800M -8.55400M -10.54200M -6.94500M -3.51234M
Change in cash -1.85400M 0.33M -13.55100M 15.42M -0.17522M
Begin period cash flow 5.09M 4.76M 18.32M 2.90M 3.07M
End period cash flow 3.24M 5.09M 4.76M 18.32M 2.90M
Total cash from operating activities -9.15500M -5.84100M -10.78000M -5.45000M -1.85664M
Issuance of capital stock 6.42M 0.00000M 6.00M 20.00M 0.00042M
Depreciation 0.45M 0.50M 0.34M 0.17M 0.17M
Other cashflows from investing activities 0.10M 0.29M 0.11M 0.00100M 0.00298M
Dividends paid - - - - -
Change to inventory 0.29M 0.36M 0.59M 0.59M 0.59M
Change to account receivables -0.90100M 0.28M -0.04800M -1.25700M 0.38M
Sale purchase of stock - - - - 0.00042M
Other cashflows from financing activities -0.77800M -0.21800M -0.54500M 0.93M 1.77M
Change to netincome - - -0.20200M 0.97M -0.02018M
Capital expenditures 0.02M 0.15M 0.34M 0.07M 0.05M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.52700M 0.89M -1.65900M -0.41900M 0.75M
Stock based compensation 0.16M 0.64M 0.50M 0.48M 0.32M
Other non cash items 3.39M 0.69M 0.58M 0.51M 0.08M
Free cash flow -9.17800M -5.99200M -11.12500M -5.51900M -1.90894M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AREC
Arecor Therapeutics PLC		 3.00 4.55% 69.00 - - 4.92 8.72 4.59 -7.3253
GNS
Genus PLC		 - -% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 -9.7 6.93% 130.30 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 30.00 5.00% 630.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 1.50 2.14% 71.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products. In addition, the company is developing AT247, an ultra-rapid acting insulin, which is in Phase 1 for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel thermostable insulin for implantable pump delivery. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Arecor Therapeutics PLC

Chesterford Research Park, Little Chesterford, United Kingdom, CB10 1XL

Key Executives

Name Title Year Born
Dr. Sarah Jennifer Howell Ph.D. CEO & Director 1976
Ms. Susan Day Lowther FCMA CFO, Company Sec. & Director 1960
Dr. Jan Jezek Ph.D. Chief Scientific Officer NA
Dr. Sarah Jennifer Howell Ph.D. CEO & Executive Director 1975
Mr. David J. Ellam CFO & Executive Director 1964
Mr. David Gerring Chief Development Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions